Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.47 |
| ▸ | CA9 | Q16790 | 10/20 | 0.47 |
| ▸ | CA1 | P00915 | 9/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207099 | 0.81 | PPARG (0.43) | SLC22A12RXRARXRBRXRGPPARG | |
| SCHEMBL29184018 | 0.81 | PPARG (0.43) | SLC22A12RXRARXRBRXRGPPARG | |
| SCHEMBL4874803 | 0.81 | CA2 (0.51) | CA2CA9CA1RXRARXRB | |
| SCHEMBL6941315 | 0.81 | SLC22A12 (0.40) | SLC22A12RXRARXRBRXRGPPARG | |
| Iodide SCHEMBL7773907 | 0.79 | PPARG (0.42) | SLC22A12RXRARXRBRXRGPPARG | |
| SCHEMBL15763987 | 0.79 | PPARG (0.42) | SLC22A12RXRARXRBRXRGPPARG | |
| SCHEMBL9451267 | 0.79 | CA2 (0.61) | CA2CA9CA1 | |
| SCHEMBL15453622 | 0.78 | ALDH1A1 (0.53) | SLC22A12RXRARXRBRXRGPPARG | |
| SCHEMBL15453625 | 0.78 | RXRA (0.41) | SLC22A12RXRARXRBRXRGPPARG | |
| SCHEMBL15453683 | 0.78 | MEN1 (0.49) | SLC22A12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | CA2 1381/4885CA9 1834/4885CA1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.